LY3325656 - CAS 1998714-25-2

LY3325656 is a GPR142 agonist suitable for clinical testing in human. LY3325656 demonstrated anti-diabetic benefits in pre-clinical studies and ADME/PK properties suitable for human dosing. LY3325656 is the first GPR142 agonist molecule advancing to phase 1 clinic trials for the treatment of Type 2 diabetes.

Others

Others

1998687

C21H23F3N6O2

448.44

CC1=C(N(C)C=N1)C=2NC(=NN2)[C@@H]3C[C@H](N(C(=O)C4=CC(C(F)(F)F)=CC=C4)C)CCO3

-20°C

Ice Packs

Small Compound